12:00 AM
 | 
Aug 13, 2012
 |  BioCentury  |  Emerging Company Profile

Inform Genomics: SNPing side effects

Inform Genomics using SNP networks to predict chemotherapy side effects

Inform Genomics Inc. is developing its OnPART test to predict which cancer patients are most likely to have chemotherapy side effects and allow doctors to treat the unwanted effects earlier or change the chemotherapy regimens they had planned to use.

OnPART (Oncology Preferences And Risk of Toxicity) uses a chip to screen a patient's saliva against a network of SNPs associated with six common side effects of chemotherapy: nausea and vomiting, diarrhea, oral mucositis, fatigue, neuropathy and cognitive dysfunction.

The company's personalized approach includes a questionnaire for the oncologist to document what side effects each patient most wants to avoid.

The chip will be screened with the patient's DNA at a CLIA lab and the results delivered to the doctor in about five to seven days. The report will list the different treatment regimens, the patient's risk for developing side effects associated with the regimens and how the patient ranks their desire to avoid those effects.

In the discovery phase for OnPART, Inform is identifying the full network of SNPs associated with the six...

Read the full 855 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury

Article Purchase

$150 USD
More Info >